Nutraceutix Gets U.S. Patent for BIO-tract Probiotic Technology

October 19, 2011

BIO-tract tablets protect probiotics from damaging stomach acids, releasing live organisms over time to the upper and lower intestinal tracts.

Nutraceutix Inc. (Redmond, WA) has obtained a U.S. patent (No. 8,007,777; “Delivery System for Biological Component”) for its BIO-tract probiotic technology. The company has four other international patents for BIO-tract, in China, Australia, Russia, and Singapore, with other patents pending.

Unlike powders, capsules, and cultured foods, BIO-tract tablets protect probiotics from damaging stomach acids, releasing live organisms over time to the upper and lower intestinal tracts, the company says. BIO-tract also benefits from Nutraceutix’s LiveBac process, which is said to extend probiotic shelf life beyond other supplement forms, even at room temperature.

“BIO-tract caplets with LiveBac processing are unparalleled when it comes to the effective delivery of live probiotic organisms to the body,” stated Tim Gamble, Nutraceutix’s president and CEO, in a press release.

Related Content:

News